The Food and Drug Administration has cited the former Mutual Pharmaceutical Co. drug-manufacturing plant in Northeast Philadelphia with “significant violations” of good manufacturing practices for pharmaceuticals.
The FDA sent a “warning letter” to the plant’s new owner, Frontida BioPharm in Exton, which on June 3bought manufacturing plants at 1100 Orthodox Street in Philadelphia and in Aurora, Ill., along with 15 pharmaceutical products. Financial terms were not disclosed.
The FDA last year inspected the Orthodox Street facility, between June 15, and July 17, 2015, then owned by Mutual Pharmaceutical, a subsidiary of Sun Pharma.
